A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

NCT04143945 on ClinicalTrials.gov · last registry update 2021-01-20

Finished 4 January 2020, after enrolling 104 people. Primary outcome, as filed: Intensity of Injection Site Pain. semaglutide is already approved in the US for obesity and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 104
Started: 2019-10-28
Primary completion: 2020-01-04 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Intensity of Injection Site Pain

Conditions studied

Healthy Volunteers Diabetes Mellitus, Type 2 · Healthy Volunteers Overweight · Healthy Volunteers Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.